GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prostatype Genomics AB (OSTO:PROGEN) » Definitions » ROE % Adjusted to Book Value

Prostatype Genomics AB (OSTO:PROGEN) ROE % Adjusted to Book Value : -110.10% (As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Prostatype Genomics AB ROE % Adjusted to Book Value?

Prostatype Genomics AB's ROE % for the quarter that ended in Jun. 2023 was -170.66%. Prostatype Genomics AB's PB Ratio for the quarter that ended in Jun. 2023 was 1.55. Prostatype Genomics AB's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 was -110.10%.


Prostatype Genomics AB ROE % Adjusted to Book Value Historical Data

The historical data trend for Prostatype Genomics AB's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prostatype Genomics AB ROE % Adjusted to Book Value Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
- - -18.75 -50.40 -229.65

Prostatype Genomics AB Quarterly Data
Jun18 Jun19 Mar20 Jun20 Sep20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -77.99 -58.05 -238.02 -110.10 -

Competitive Comparison of Prostatype Genomics AB's ROE % Adjusted to Book Value

For the Diagnostics & Research subindustry, Prostatype Genomics AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prostatype Genomics AB's ROE % Adjusted to Book Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Prostatype Genomics AB's ROE % Adjusted to Book Value falls into.



Prostatype Genomics AB ROE % Adjusted to Book Value Calculation

Prostatype Genomics AB's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-163.05% / 0.71
=-229.65%

Prostatype Genomics AB's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-170.66% / 1.55
=-110.10%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prostatype Genomics AB ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Prostatype Genomics AB's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Prostatype Genomics AB (OSTO:PROGEN) Business Description

Traded in Other Exchanges
Address
Gustaf III:s Boulevard 34, Solna, SWE, 169 73
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.

Prostatype Genomics AB (OSTO:PROGEN) Headlines

No Headlines